Daily Stock Analysis, BNDX, Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York., priceseries

Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.. Daily Stock Analysis
Stock Information
Open
58.25
Close
58.29
High
58.30
Low
58.22
Previous Close
58.15
Daily Price Gain
0.14
YTD High
59.22
YTD High Date
Sep 3, 2019
YTD Low
53.62
YTD Low Date
Jan 8, 2019
YTD Price Change
4.42
YTD Gain
8.21%
52 Week High
59.22
52 Week High Date
Sep 3, 2019
52 Week Low
52.81
52 Week Low Date
Oct 23, 2018
52 Week Price Change
5.48
52 Week Gain
10.37%
Company Information
Stock Symbol
BNDX
Exchange
NYSE
Company URL
http://www.bms.com
Company Phone
2125464000
CEO
Giovanni Caforio
Headquarters
New York
Business Address
345 PARK AVE, NEW YORK, NY 10154
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0000014272
About

Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.